Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class III · Low risk Terminated Initiated Apr 1, 2022 (5 years ago)

Methylprednisolone Tablets

Class III — Low risk. Unlikely to cause harm, but violates FDA regulations.

Why it was recalled

Subpotent

Cause type: Wrong potency / content

Sub- or super-potent product, or a failed content-uniformity / assay test. You may receive too little or too much active ingredient - a direct dosing risk. All wrong potency / content recalls.

What was recalled

Methylprednisolone Tablets, USP 4mg, 100-count bottle, Rx Only, Manufactured by: Jubliant Cadista Pharmaceuticals Inc. Salisbury, MD 21801, USA, NDC 59746-001-06

Affected NDC 59746-0001-06

Compare with the code on your package — it is the most precise check available.

Drug: Methylprednisolone

Recalling firm
Jubilant Cadista Pharmaceuticals, Inc.
NDC code
59746-001-06
Origin
MD, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0752-2022 · FDA notice

Low risk, still worth a check. Class III means the product is unlikely to cause harm but breaks an FDA rule (often labeling). If your lot matches, your pharmacy will normally swap it; there is no need for alarm. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Methylprednisolone recalls

See all
Class II · Moderate risk

methylprednisolone tablets

Labeling: Not Elsewhere Classified. Incorrect orientation of the blister foil applied to the blister cavities, which results in incorrect dosing information when following the directions on the foil.

Ongoing Labeling / mix-up Greenstone Llc NDC 59762-4440-2 D-0299-2026
Class III · Low risk

Methylprednisolone Acetate Injectable Suspension

Labeling: Not Elsewhere Classified; A typographical error was observed in the NDC number on the preprinted Individual Folding Cartons (secondary packaging only). Incorrect NDC Number 70121-1573-1; Correct NDC Number 70121-1574-1.

Terminated Labeling / mix-up Amneal Pharmaceuticals of New York, LLC NDC 70121-1574-01 D-0756-2023

Other recalls by Jubilant Cadista Pharmaceuticals, Inc.

All 2022 recalls
Class II · Moderate risk

Irbesartan Tablets

Failed Dissolution Specifications

Terminated Dissolution failure Jubilant Cadista Pharmaceuticals, Inc. NDC 59746-447-90 D-1294-2022
Class II · Moderate risk

Irbesartan Tablets

Failed dissolution specifications.

Terminated Dissolution failure Jubilant Cadista Pharmaceuticals, Inc. NDC 59746-448-90 D-1293-2022
Class I · High risk

Meclizine Hydrochloride Tablets USP

Labeling: Label mix-up: Incorrect label placed on product. Shipper cases labeled Meclizine Hydrochloride Tablets contain bottles incorrectly labeled as PredniSONE Tablets. The tablets in the bottles are Meclizine Hydrochloride

Terminated Labeling / mix-up Jubilant Cadista Pharmaceuticals, Inc. NDC 59746-122-06 D-0767-2022